symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
LYEL,1.58,-1.112343,717125,396622673,0,1.32-7.078,-0.03,"Lyell Immunopharma, Inc.",USD,0001806952,US55083R1041,55083R104,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.lyell.com,"Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.","Dr. Lynn  Seely M.D., Ph.D.",Healthcare,US,274,650 695 0677,201 Haskins Way,South San Francisco,CA,94080,,0,https://financialmodelingprep.com/image-stock/LYEL.png,2021-06-17,False,False,True,False,False
